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Abstract 
Background: Genetic analysis of advanced cancer is limited by availability of representative tissue. Biopsies of 
prostate cancer metastasized to bone are invasive with low quantity of tumor tissue. The prostate cancer genome 
is dynamic, however, with temporal heterogeneity requiring repeated evaluation as the disease evolves. Circulating 
tumor cells (CTCs) offer an alternative, “liquid biopsy”, though single CTC sequencing efforts are laborious with high 
failure rates.
Methods: We performed exome sequencing of matched treatment-naïve tumor tissue, castrate resistant tumor tis-
sue, and pooled CTC samples, and compared mutations identified in each.
Results: Thirty-seven percent of CTC mutations were private to CTCs, one mutation was shared with treatment-naïve 
disease alone, and 62% of mutations were shared with castrate-resistant disease, either alone or with treatment-naïve 
disease. An acquired nonsense mutation in the Retinoblastoma gene, which is associated with progression to small 
cell cancer, was identified in castrate resistant and CTC samples, but not treatment-naïve disease. This timecourse cor-
related with the tumor acquiring neuroendocrine features and a change to neuroendocrine-specific therapy.
Conclusions: These data support the use of pooled CTCs to facilitate the genetic analysis of late stage prostate 
cancer.
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Background
Prostate cancer biology is initially dominated by activity 
of the androgen receptor (AR), and androgen depriva-
tion therapy (ADT) is the backbone of therapy for those 
with metastatic prostate cancer. Castrate resistance is 
nearly universal, however, requiring additional manage-
ment decisions. The heterogeneity of primary prostate 
cancer is well established [1–3], and polyclonal seeding 
of metastatic sites, and metastasis-to-metastasis spread, 
appear to be possible, if not common [4]. Moreover, the 
prostate cancer genome is dynamic, with different clones 
dominating over time in response to different lines of 
therapy [5, 6]. As the number of approved agents that 
prolong survival increases, the dynamic clonal nature 
of this disease is likely to become a greater issue. For 
example, there appears to be a new entity, intermediate 
between conventional adenocarcinoma and classic neu-
roendocrine disease, that arises with resistance to newer 
AR-targeted agents [7].
Circulating tumor cells (CTCs) and cell free DNA 
(cfDNA) are emerging as non-invasive alternative means 
to interrogate the genetics of late stage disease rather 
than invasive and/or risky biopsy of metastatic disease. 
They are complimentary methods, each with advantages 
and disadvantages. The dilute tumor fraction of cfDNA 
in most patients requires very high sequencing cover-
age to detect mutations, typically limiting analysis to a 
small number of targeted regions [5]. On the other hand, 
amplifying DNA from single circulating tumor cells is 
inconsistent and low yield. Successful efforts from indi-
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or pooled the results from 19 separately sequenced 
CTCs [8, 9]. We present here whole exome sequencing of 
pooled CTCs, with matched treatment-naïve and castrate 
resistant tissue, demonstrating identification in pooled 
CTCs of clinically relevant mutations acquired late in the 
course of disease.
Methods
Patient recruitment and patient samples
The patient provided written informed consent and was 
enrolled in the “Prostate Cancer Sample Collection” pro-
tocol of the University of Chicago Medical Center, which 
was approved by the University of Chicago ethics com-
mittee (approval reference number 13-1295). Biopsy 
specimens were processed per clinical protocols includ-
ing hematoxylin and eosin stain and immunohistochemi-
cal analysis of PSA expression. Circulating tumor cells 
were collected as previously described [10]. In short, 
mononuclear cells were enriched from 15 ml peripheral 
blood and stained with an Alexa-488 conjugated EpCAM 
antibody (Biolegend, 1:100) and a QDot800 conjugated 
CD45 antibody (Invitrogen, 1:100). CTCs were isolated 
by FACS-sorting EpCAM+/CD45− cells on a MoFlo 
XDP flow-sorting machine. One thousand WBCs were 
isolated by FACS-sorting EpCAM−/CD45+ cells as rep-
resentative of germline DNA.
Whole genome amplification and exome sequencing
Isolated EpCAM+/CD45− CTCs were divided into three 
equal samples of 500 cells each and independently sub-
jected to whole genome amplification (WGA) through 
multidisplacement amplification using REPLI-G (Qia-
gen), following the manufacturer’s instructions, as were 
EpCAM−/CD45+  WBCs representative of germline. 
The quality of amplification was evaluated through PCR 
amplification of eight targets [11] to evaluate uniform 
amplification across multiple chromosomes, and length 
of amplification product. Primers used are listed in Addi-
tional file  1. Exome sequencing libraries were prepared 
using NEB Next Ultra (New England Biolabs) kit follow-
ing the manufacturer’s instructions. Sequencing was per-
formed on a HiSeq 2000 (Illumina).
Sequencing analysis
Illumina sequencing data was mapped to the GRCh37 
version of the human reference genome using BWA–
MEM [12] and further processed following the GATK 
Best Practices [13]. Somatic variants were called for each 
tumor or CTC sample in a paired manner using MuTect 
[14] in high confidence mode. Potential germline vari-
ants were removed by excluding positions with germline 
coverage <20×, variant reads in the germline, or variants 
present in dbSNP, and remaining variants were enriched 
for highest confidence by including only variants in the 
exome and with 5 or more supporting reads comprising 
10% or more of all reads. Somatic mutations passing all 
filters (listed in Additional file 2) in a given sample were 
then examined for the presence/absence of supporting 
reads in other samples using samtools mpileup [15, 16]. 
Mutations were visually verified by examining supporting 
reads using Alview [17], and all somatic mutations were 
annotated using AVIA [18].
Results
A 70 year old patient was diagnosed with metastatic pros-
tate cancer, confirmed with biopsy of a bone metastasis 
(Fig.  1a). He underwent androgen deprivation therapy 
but eventually developed castrate resistant prostate can-
cer (CRPC). Additional conventional therapies yielded 
short-lived responses and subsequent progression of dis-
ease (Fig. 1b). A liver biopsy performed 22 months after 
the initial diagnosis confirmed metastatic prostate cancer 
(Fig. 1c), but with neuroendocrine and small cell features, 
which was not appreciated on the initial biopsy. Given 
the change in dominant histology he started treatment 
with carboplatin and etoposide, but after two cycles he 
entered hospice care.
To evaluate the extent to which the current disease 
biology can be discovered through CTCs, CTCs were col-
lected from 15 ml of peripheral blood within a month of 
the liver biopsy. CTCs were enriched by FACS-sorting 
EpCAM+/CD45− cells as previously described [10] and 
divided into three equal fractions. Multidisplacement 
amplification was used to amplify the entire genome 
of each fraction independently. To evaluate for loss of 
coverage due to lack of amplification and for length of 
amplified fragments, the amplified CTC genomes were 
evaluated with endpoint PCR for eight targets of vary-
ing lengths across six different chromosomes (Fig.  1d). 
More targets were able to be amplified from one CTC 
pool (CTC1) than the other two pools (CTC2, CTC3). All 
three samples were used for exome sequencing.
Whole exome sequencing was performed on a ger-
mline sample and five tumor samples: initial diagnos-
tic, treatment-naive biopsy of an ischial metastasis; liver 
biopsy of CRPC; and three samples of pooled CTCs 
divided from a single CTC collection. The fractions of 
PCR duplicates were all 0.25 or less (Fig.  2a). Adequate 
coverage was obtained for the germline sample, the tis-
sue samples, and CTC1, samples that were predicted to 
perform well by initial evaluation, with coverage of over 
98% of the genome, median depths of 44–106×, and 
10× coverage of 90% or more of the exome (Fig. 2b). The 
lower quality CTC samples covered just 37 and 40% of 
the exome at 10×. Due to their poor quality they were 
left out of downstream analysis. Mutation patterns were 
Page 3 of 8Lack et al. J Transl Med  (2017) 15:44 
consistent in the treatment-naïve, CRPC, and CTC sam-
ple, including nucleotide substitutions (Fig. 2c) and type 
of mutation (Fig. 2d).
The allele frequency was comparable for mutations in 
the tissue specimens, but higher in the CTCs (Fig.  3a). 
Moreover, while trunk mutations (those found in both 
treatment-naïve and CRPC tissue samples) were near 
50% allele frequency, suggesting close to 100% pure CTCs 
all with one allele mutated, branch (shared with one tis-
sue sample) and leaf (found only in CTCs) mutations 
were at lower allele frequency, indicating genetic hetero-
geneity among CTCs (Fig. 3b).
There was considerable genetic heterogeneity among 
tumor tissue samples, with just 8% of mutations being 
trunk mutations, and 25% being found in two samples. 
Thirty-six percent of mutations from CRPC were not 
initially identified in the treatment-naive sample but had 
at least two reads supporting their presence, indicating 
enrichment in the CRPC tissue of subclonal populations 
from the treatment-naive tissue. The reverse—mutations 
identified in the treatment-naive sample with low fre-
quency supporting reads in CRPC—was not identified 
(Fig.  3c, d). The pooled CTCs identified 71% of muta-
tions shared by treatment-naïve and CRPC tissue sam-
ples, suggesting most mutations at high allele frequency 
(early mutations) were represented in the CTCs (Fig. 3e). 
Examining the two low quality CTC pools, each pool 
identified 22% of trunk mutations, consistent with their 
10x coverage being 37–40% of the genome. All the trunk 
mutations identified in the low quality pools were also 
identified in the high quality pool, suggesting consistency 
in the mutations able to be identified by CTCs.
The CTCs had the highest fraction of mutations shared 
with at least one other sample, at 64% (Fig. 3f ). Fifty per-
cent were trunk mutations, shared with both tissue sam-
ples, and an additional 14% were shared with the CRPC 
Fig. 1 Clinical timecourse of disease. a Hematoxylin-Eosin stain (top) and immunohistochemical analysis of PSA protein (bottom) of treatment-naive 
bone biopsy diagnosing metastatic prostate cancer. b Clinical timecourse indicating PSA levels, timing of biopsies, timing of the single CTC collec-
tion ~3 weeks after CRPC biopsy, which was divided into three pools, and timing of therapies. CAB combined androgen blockade, abi abiraterone, 
doc docetaxel, RT palliative radiation therapy, CE carboplatin and etoposide. c CT image of liver metastasis that underwent biopsy (white arrowhead). 
d Fraction of PCR targets that were amplified from each whole genome amplification product
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sample alone. A single mutation was shared between 
CTCs and treatment-naïve tissue and not found in CRPC 
tissue. Though the other two CTC samples had poor 
exome coverage and were not of sufficient quality to 
identify mutations a priori, 33% of mutations identified in 
the high quality CTC sample were also identified in one 
of the low quality CTC samples.
One of the mutations shared between the CRPC tis-
sue sample and CTCs was a premature stop codon in the 
Retinoblastoma (RB1) gene (Fig. 4a), which is associated 
with isolated bilateral retinoblastoma and meningioma 
[19]. The appearance of this RB1 mutation coincided with 
loss of adenocarcinoma features, including PSA expres-
sion (compare Fig. 4b, top and middle panels, to Fig. 1a), 
and gain of neuroendocrine features in the tumor, which 
was confirmed by synaptophysin expression (Fig.  4b, 
bottom panel). This phenotypic change toward therapy-
emergent neuroendocrine prostate cancer prompted a 
change in management strategy away from standard of 
care for CRPC.
Discussion
The prostate cancer genome is heterogeneous, both 
between and within the multiple foci characteristic of 
primary disease. The clonal architecture of advanced 
disease is dynamic, with new clones gaining dominance 
in response to new therapies. Combined, these neces-
sitate repeated genomic or molecular assessments over 
the course of disease in order to have a complete, current 
understanding of a patient’s personalized disease.
Circulating tumor cells offer a non-invasive mecha-
nism to repeatedly evaluate the shifting dynamics of 
disease. This has demonstrated clinically meaningful 
evaluations of specific alterations [20, 21]. However, 
there have been few direct correlations between treat-
ment-naïve tissue, CTCs, and contemporaneous CRPC 
tissue, and wider scale genomic evaluations are still in 
early stages. Lohr et al. used whole genome sequencing 
to evaluate quality of amplified DNA followed by exome 
sequencing of 19 individual CTCs to demonstrate late 
divergence of CTCs and a previously resected lymph 
node [8]. Jiang et al. used laser capture microdissection 
to capture and evaluate 99 individual CTCs collected 
over five blood collections, identifying four individual 
CTCs with high quality DNA and eight with moder-
ate quality [9]. The CTCs in that study identified 15% of 
trunk SNVs, with supporting reads for an additional 14% 
of reads.
Using our pooled CTC strategy, we generated suc-
cessful sequencing libraries from 33% of samples. The 
Fig. 2 Similar sequencing library characteristics from tissue and one of three CTC pool sequencing libraries. a Fraction of sequencing libraries 
consisting of PCR duplicates. b Coverage plots for germline, treatment-naïve (Rx-naïve) tissue, advanced cancer (CRPC) tissue, and three CTC pool 
sequencing libraries. c Transitions and transversions and d mutation types among the variants identified in the two tissue and CTC1 sequencing 
library
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sequencing demonstrated high correlation with tis-
sue samples, confirming the biological relevance of 
the CTC exomes, identifying 71% of trunk mutations, 
along with additional mutations acquired later in dis-
ease. This includes a clinically meaningful mutation 
in RB1 which likely contributed to a change in pheno-
type to neuroendocrine features, prompting a change 
in management strategies. The RB1 gene is altered in 
nearly 9% of advanced prostate cancer cases, through 
deletion, frameshift mutations, and introductions of 
premature stop codons [22]. Beltran et  al. compared 
advanced prostate neuroendocrine and adenocarcinoma, 
demonstrating that RB1 alterations are significantly 
enriched in advanced prostate cancer with neuroendo-
crine features (70% altered) compared to that with pure 
adenocarcinoma features (32% altered) [23]. Loss of RB1 
function is common in primary small cell cancer of the 
prostate or lung, and in animal models it promotes devel-
opment of small cell carcinoma [24, 25].
The clonal relationship among all three specimens sug-
gest that neuroendocrine disease arose from adenocarci-
noma, rather than being a coincident, independent clone. 
In addition, the high frequency of mutations in CRPC tis-
sue that were present at low frequency in treatment-naïve 
Fig. 3 Circulating tumor cells pool captures majority of trunk mutations and additional mutations from metastatic disease. a Variant allele frequen-
cies for treatment-naïve, CRPC, and CTC1 mutations. b Average variant allele frequencies of trunk, branch, and leaf mutations in two tissue samples 
and one CTC sample. c Allele fraction in CRPC tissue of mutations identified in treatment-naïve tissue, and d vice versa. On the left are mutations 
identified in both samples. On the right are mutations identified in only sample. In d, many of the mutations not identified independently in treat-
ment-naïve tissue had evidence they were present at low allele frequency. e Number of trunk mutations identified in three pooled CTC sequencing 
libraries. f Fraction of CTC mutations shared with other tissue samples
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tissue supports the idea that advanced disease, includ-
ing neuroendocrine disease, arises from subclonal 
population(s) in the initial specimen. Of note, though 
CTCs from patients with neuroendocrine prostate cancer 
are more frequently nonclassical than those with patients 
with adenocarcinoma (17), the RB1 mutation was identi-
fied in classical EpCAM+ CTCs.
Fewer mutations were identified in CTCs than in treat-
ment-naïve or CRPC tissue samples. The significance of 
this is unclear. It may be that the limited number of CTCs 
was unable to capture the extensive diversity of clones 
comprising disease in the tissue. Alternatively, it may be 
that CTCs represent a limited number of aggressive and 
clinically relevant clones. The CTCs were not clonal, as 
evidenced by the presence of branch and leaf mutations. 
This genetic heterogeneity among CTCs is supported by 
Massard et al. [26] based on a single genomic alteration, 
the ERG alteration pattern. The extent to which CTCs 
represent all the relevant subclones needs to be explored 
further.
There are several advantages of a pooled CTC strat-
egy over single CTC sequencing, including availability 
of resources. Our strategy relied on FACS-sorting and 
whole genome amplification using a commercially avail-
able kit, which are readily available to most research-
ers. We did not require laser capture microdissection or 
robotic micromanipulation. Disadvantages include appli-
cability limited to patients with a higher burden of CTCs 
and inability to fully characterize heterogeneity at the cel-
lular level.
While we had a much higher success rate sequencing 
pooled CTCs than has been reported with single CTC 
Fig. 4 Identification of RB1 nonsense mutation in CRPC tissue and CTC samples. a Integrative Genomics Viewer [28] images of the S816X mutation 
identified in CRPC and CTC1, but not treatment-naïve sample. The brown bars in the middle panels represent the mutated nucleotide and its posi-
tion within the sequencing reads. The histograms in the upper panels summarize the fraction of reference (gray or blue) or mutated (brown) reads. b 
Hematoxylin-Eosin stain (top) and immunohistochemical analysis of PSA (middle) or synaptophysin protein (bottom) of the CRPC liver biopsy
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sequencing, only one of three pools provided high qual-
ity data. This may have been due in part to our multiple 
displacement amplification strategy [27]. This was chosen 
for the low error rate of its polymerase, but it may be less 
reliable in amplifying the majority of the genome com-
pared to PCR-based methods.
As the number of effective therapies used for treat-
ment of advanced prostate cancer increases, there is 
an increasing appreciation of the dynamic nature of 
the genomics of advanced disease in response to thera-
peutic pressure. We demonstrate here that sequencing 
pooled CTCs is a feasible, noninvasive, and informa-
tive way to evaluate the current molecular features of 
advanced disease.
Conclusions
The histology, behavior, and genomics of advanced pros-
tate cancer evolve in response to therapeutic pressure. 
Pooled CTCs are a feasible, non-invasive way to interro-
gate the molecular characteristics of advanced prostate 
cancer.
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